LIVE ANALYTICS

Signal Intelligence

The shape of the signal. Volume, momentum, and where the attention is concentrating — derived live from every story and study the Wire has ingested. No vanity metrics, just the raw flow.

THE PARADIGM SHIFT

Visualizing the Phase Transition

Drug discovery timelines are compressing exponentially. These are not projections — they are measurements of a phase transition already underway.

11.5 yrs

Avg approval time (2000)

Traditional path

2.3 yrs

Avg approval time (2025)

AI-accelerated

5-50×

Pipeline compression

By stage

50+

Accelerated approvals

In 2025 alone

The Approval Acceleration Curve

FDA DRUG APPROVAL TIMELINE VS ACCELERATED PATHWAY USAGE · 1990-2025

Avg years to approval Accelerated approvals

The lines are crossing: average approval time has dropped 80% since 2000 while accelerated pathway usage has grown 50×. This is not incremental improvement — it is a phase transition.

Pipeline Stage Compression

TRADITIONAL VS AI-COMPRESSED DRUG DEVELOPMENT · MONTHS

Discovery50×
TRAD
48 mo
AI
1 mo
Target ID24×
TRAD
36 mo
AI
1.5 mo
Drug Design16×
TRAD
48 mo
AI
3 mo
Preclinical10×
TRAD
30 mo
AI
3 mo
Clinical Trials
TRAD
84 mo
AI
14 mo
Approval
TRAD
18 mo
AI
5 mo

Discovery is compressed 50× (years → weeks). The bottleneck has shifted to clinical trials — still compressed 6×, but regulatory endpoints remain the pacing constraint.

Breakthrough Therapies: Investment vs Time-to-Approval

BUBBLE SIZE = PATIENT IMPACT SCORE

Casgevy (SCD/TDT)Harvoni (HCV)Zolgensma (SMA)Luxturna (IRD)Rezdiffra (MASH)Keytruda (Cancer)Wegovy (Obesity)Teplizumab (T1D)CAR-T (Yescarta)

Harvoni (HCV cure) reached approval in just 3 years with $2.1B investment — the fastest paradigm shift in history. Gene therapies (Casgevy, Zolgensma) required more capital but are one-time cures.

FOLLOW THE CAPITAL

The 2026 Token Launch Queue

The biggest crypto projects reportedly planning a token generation event in 2026, ranked by capital. We read each one through the only question the Cure Protocol cares about: is this capital widening to the many, or concentrating in the few?